|
gptkbp:instance_of
|
gptkb:legal_case
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Imfinzi
|
|
gptkbp:analysis
|
Cox proportional hazards model
|
|
gptkbp:analyzes
|
gptkb:Dr._David_Spigel
|
|
gptkbp:clinical_trial
|
NC T03043872
demonstrated efficacy of durvalumab
|
|
gptkbp:collaborations
|
gptkb:temple
gptkb:European_Organization_for_Research_and_Treatment_of_Cancer
gptkb:healthcare_organization
|
|
gptkbp:collection
|
clinical assessments
|
|
gptkbp:end_date
|
gptkb:2020
|
|
gptkbp:events
|
at least 2 years
|
|
gptkbp:focuses_on
|
small cell lung cancer
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CASPIAN trial
|
|
gptkbp:is_compared_to
|
durvalumab plus chemotherapy vs chemotherapy alone
|
|
gptkbp:is_monitored_by
|
serious adverse events
|
|
gptkbp:is_protected_by
|
parallel assignment
|
|
gptkbp:is_studied_in
|
multicenter, randomized
Phase III trial
|
|
gptkbp:is_tested_for
|
Phase III
|
|
gptkbp:launch_date
|
gptkb:2017
|
|
gptkbp:location
|
multiple countries
|
|
gptkbp:participants
|
approximately 800
overall response rate
overall survival
progression-free survival
|
|
gptkbp:population
|
patients with untreated SCLC
|
|
gptkbp:products
|
gptkb:cisplatin
gptkb:etoposide
gptkb:durvalumab
gptkb:carboplatin
|
|
gptkbp:provides_information_on
|
data available upon request
influenced treatment guidelines for SCLC
|
|
gptkbp:publishes
|
gptkb:Lancet_Oncology
published in peer-reviewed journal
|
|
gptkbp:receives_funding_from
|
funded by Astra Zeneca
|
|
gptkbp:recorded_by
|
1:1 ratio
|
|
gptkbp:regulatory_compliance
|
FDA approval for durvalumab
|
|
gptkbp:research
|
improved treatment options for SCLC
showed improved survival
|
|
gptkbp:research_focus
|
combination therapy
|
|
gptkbp:result
|
gptkb:2020
interim results
|
|
gptkbp:safety_features
|
monitoring for toxicity
|
|
gptkbp:sponsor
|
gptkb:temple
|
|
gptkbp:student_enrollment
|
adults with extensive-stage SCLC
no prior systemic therapy
|
|
gptkbp:treatment
|
gptkb:durvalumab
chemotherapy
two treatment arms
|
|
gptkbp:vision
|
open-label
|
|
gptkbp:year
|
gptkb:2019
gptkb:2020
|